BSX - Boston Scientific Corporation

NYSE - NYSE Delayed Price. Currency in USD
43.71
-0.37 (-0.84%)
At close: 4:00PM EST

43.71 0.00 (0.00%)
After hours: 7:10PM EST

Stock chart is not supported by your current browser
Previous Close44.08
Open44.07
Bid43.69 x 900
Ask43.70 x 3100
Day's Range43.66 - 44.17
52 Week Range31.56 - 44.22
Volume9528519
Avg. Volume7,036,410
Market Cap61B
Beta (3Y Monthly)0.78
PE Ratio (TTM)56.77
EPS (TTM)0.77
Earnings DateFeb 4, 2020 - Feb 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est48.36
  • South Texas Military Contracting Roundup: more than $46M in contracts awarded
    American City Business Journals

    South Texas Military Contracting Roundup: more than $46M in contracts awarded

    This week's military contracting roundup features three contract notices for food distribution, staffing of certified registered nurse anesthetists and neurostimulator implantable devices, as well as solicitations for four contracts at Joint Base San Antonio.

  • Calculating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
    Simply Wall St.

    Calculating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)

    Does the December share price for Boston Scientific Corporation (NYSE:BSX) reflect what it's really worth? Today, we...

  • Boston Scientific's Watchman Implant Study Results Encourage
    Zacks

    Boston Scientific's Watchman Implant Study Results Encourage

    These study results are expected to be a major breakthrough for Boston Scientific's (BSX) Cardiovascular segment.

  • Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018​
    American City Business Journals

    Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018​

    The drug makers and medical device firms that made the most payments to District physicians and health systems last year include a handful of industry giants with deep local ties.

  • Urbem's 'Wonderful Business' Series: Intuitive Surgical
    GuruFocus.com

    Urbem's 'Wonderful Business' Series: Intuitive Surgical

    A near-monopoly pioneer in a fast-growing space Continue reading...

  • Is Boston Scientific Corporation (BSX) A Good Stock To Buy?
    Insider Monkey

    Is Boston Scientific Corporation (BSX) A Good Stock To Buy?

    While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and deteriorating expectations towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the third quarter and hedging or reducing many of […]

  • Boston Scientific (BSX) Up 4.5% Since Last Earnings Report: Can It Continue?
    Zacks

    Boston Scientific (BSX) Up 4.5% Since Last Earnings Report: Can It Continue?

    Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Boston Scientific to Participate in Evercore ISI and Piper Jaffray Healthcare Conferences
    PR Newswire

    Boston Scientific to Participate in Evercore ISI and Piper Jaffray Healthcare Conferences

    MARLBOROUGH, Mass. , Nov. 21, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in two investor conferences this December. On Wednesday, December 4, 2019 , Susie ...

  • Safety Notice Issued by Boston Scientific (BSX) for AngioJet
    Zacks

    Safety Notice Issued by Boston Scientific (BSX) for AngioJet

    Boston Scientific (BSX) issues an urgent field safety notice for AngioJet Ultra consoles.

  • The 13 Best Health-Care Stocks to Buy for 2020
    Kiplinger

    The 13 Best Health-Care Stocks to Buy for 2020

    One of the most attractive reasons to invest in health-care stocks continues to be the world's aging population.The United Nations says people age 65 and older are the fastest-growing age group worldwide. It estimates that by 2050, one out of every six people will be 65 or older, accounting for 16% of the planet's total population, up from 9% in 2011. That figure is even larger in Europe and North America, where the U.N. predicts the number will be closer to 25%. The demand for health-care products and services should only increase as a result.Yes, health-care stocks will be coming off a weak 2019. Through mid-November, the S&P; 500 was sitting on nearly 25% gains, while the sector had improved by roughly half that. They'll also have to contend with uncertainty regarding the future of health care as the 2020 presidential election approaches. But don't sleep on the space in the year ahead.For one, health-care stocks tend to outperform during periods of economic weakness. For instance, the Health Care Select Sector SPDR Fund (XLV) delivered a 39.6% total loss (share price plus dividends) during the 2007-09 bear market - more than 15 percentage points better than the S&P; 500\. Thus, headlines warning of an economic slowdown or even a recession in 2020 actually bode well for the sector.Also, health care has traded at a price-to-earnings ratio more expensive than the overall market more often than not over the past 20 years. However, according to the Charles Schwab Center for Research, the sector's P/E currently is cheaper than the S&P; 500, providing a better buying opportunity.Here, then, are the 13 best health-care stocks to buy for 2020, including a couple of funds for investors who want to diversify. SEE ALSO: Every Warren Buffett Stock Ranked: The Berkshire Hathaway Portfolio

  • Reuters

    UPDATE 1-Stents no better than drugs for many heart patients -U.S. study

    Many patients with severe but stable heart disease who routinely undergo invasive procedures to clear and prop open clogged arteries would do as well by just taking medications and making lifestyle changes, U.S. researchers reported on Saturday. The $100 million government-backed study, presented at the American Heart Association (AHA) meeting in Philadelphia, is the largest yet to look at whether procedures to restore normal blood flow in patients with stable heart disease offers an added benefit over more conservative treatment with aspirin, cholesterol-lowering drugs and other measures. At least two prior studies determined that artery-clearing and stenting or bypass surgery in addition to medical treatment does not significantly lower the risk of heart attacks or death compared with non-invasive medical approaches alone.

  • Benzinga

    Large Option Traders Betting Boston Scientific Has Run Out Of Steam

    Boston Scientific Corporation (NYSE: BSX) are up 8.5% since the company reported third-quarter earnings in late October. At 10:10 a.m., a trader sold 1,656 Boston Scientific call options with a $33 strike price expiring on Jan. 17, 2020 at the bid price of 64.1 cents. At 10:12 a.m., a trader bought 620 Boston Scientific call options with a $42.50 strike price expiring on Nov. 29 near the ask price at 40.9 cents.

  • Boston Scientific Completes €900 million Offering of Senior Notes and $1.0 billion Tender Offer
    PR Newswire

    Boston Scientific Completes €900 million Offering of Senior Notes and $1.0 billion Tender Offer

    MARLBOROUGH, Mass. , Nov. 12, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) (the "Company") completed a public offering of €900.0 million aggregate principal amount of 0.625% ...

  • How Good Is Boston Scientific Corporation (NYSE:BSX), When It Comes To ROE?
    Simply Wall St.

    How Good Is Boston Scientific Corporation (NYSE:BSX), When It Comes To ROE?

    One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

  • Barrons.com

    78 Stocks in the S&P 500 Don’t Pay a Dividend. Here Are Some That Should.

    Firms have a variety of reasons for forgoing dividends. But some say Berkshire Hathaway, Facebook, and others have the means and should initiate dividends.

  • PR Newswire

    Boston Scientific Prices €900,000,000 of Senior Notes

    MARLBOROUGH, Mass., Nov. 6, 2019 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (BSX) announced the pricing of a public offering of €900,000,000 aggregate principal amount of its 0.625% notes due 2027, under the Company's shelf registration statement. The Company expects to receive the net offering proceeds upon closing on November 12, 2019, subject to customary closing conditions. The Company intends to use the net proceeds from the offering to (i) fund the previously announced tender offer for up to $1.0 billion in aggregate principal amount of certain series of the Company's senior notes (the "Tender Offer") and (ii) pay accrued and unpaid interest, premiums, fees and expenses in connection with the Tender Offer.

  • Moody's

    Boston Scientific Corporation -- Moody's assigns Baa2 rating to Boston Scientific's euro note offering

    Moody's Investors Service ("Moody's") assigned a Baa2 rating to the new senior unsecured notes offering of Boston Scientific Corporation ("Boston Scientific"). There are no changes to Moody's existing ratings of Boston Scientific including the Baa2 senior unsecured long-term rating and the Prime-2 short-term rating. Moody's views the transaction as a credit positive as it will lower Boston Scientific's interest expense.

  • PR Newswire

    Boston Scientific Announces Pricing Terms of Its Cash Tender Offer for up to $1.0 Billion of Its Outstanding Debt Securities

    MARLBOROUGH, Mass., Nov. 5, 2019 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (BSX) today announced the pricing terms of the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate principal amount (the "Aggregate Maximum Principal Amount") of the outstanding senior notes listed in the table below (the "Securities"). The table below summarizes certain information regarding the Securities and the Tender Offer, including the order of priority and purchase price information for the Securities.

  • PR Newswire

    Boston Scientific Announces Positive Data for the Ranger™ Drug-Coated Balloon and the Eluvia™ Drug-Eluting Vascular Stent at VIVA19

    LAS VEGAS and MARLBOROUGH, Mass., Nov. 5, 2019 /PRNewswire/ -- Today, Boston Scientific (BSX) announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at Vascular InterVentional Advances (VIVA) meeting in Las Vegas. The RANGER II SFA study evaluated the safety and effectiveness of the Ranger DCB, which has a low drug dose density of paclitaxel, versus standard percutaneous transluminal angioplasty (PTA) for the treatment of patients with peripheral artery disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA).

  • Which Companies Recently Raised Guidance?
    Yahoo Finance

    Which Companies Recently Raised Guidance?

    Third-quarter EPS season is in the homestretch, with blue-chip Utilities, Financial Services, Consumer and Industrial companies all releasing reports. Through 11/1/2019, Refinitiv reported that 356 S&P 500 companies have now announced 3Q earnings, with 76% coming in above consensus, ahead of the past four-quarters average percentage of 74%. The better-than-expected results have improved the overall forecast for the quarter to a -0.8%, from -3.2% at the start of the reporting season. Our analysts are always on the lookout for companies that raise their outlooks during earnings season. Management’s ability to “raise guidance” can often be a catalyst to strong returns in the quarters ahead. Following are 12 BUY-rated companies in Argus coverage for which management has raised guidance during the current EPS reporting season.

  • Boston Scientific Announces Early Results of Its Cash Tender Offer for up to $1.0 Billion of Its Outstanding Debt Securities
    PR Newswire

    Boston Scientific Announces Early Results of Its Cash Tender Offer for up to $1.0 Billion of Its Outstanding Debt Securities

    MARLBOROUGH, Mass., Nov. 5, 2019 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (BSX) today announced that, pursuant to the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate principal amount (the "Aggregate Maximum Principal Amount") of the outstanding senior notes listed in the table below (the "Securities"), approximately $1.6 billion in aggregate principal amount of the Securities were validly tendered and not validly withdrawn on or prior to 5:00 p.m., Eastern Standard Time (EST), on November 4, 2019 (the "Early Tender Date"). Withdrawal rights for the Tender Offer expired at 5:00 p.m. EST on November 4, 2019, and, accordingly, Securities validly tendered in the Tender Offer may no longer be withdrawn except where additional withdrawal rights are required by law.

  • Boston Scientific Announces November 2019 Conference Schedule
    PR Newswire

    Boston Scientific Announces November 2019 Conference Schedule

    MARLBOROUGH, Mass. , Nov. 1, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in four conferences, including one industry conference and three investor conferences, this ...

  • Thomson Reuters StreetEvents

    Edited Transcript of BSX earnings conference call or presentation 23-Oct-19 12:00pm GMT

    Q3 2019 Boston Scientific Corp Earnings Call

  • Boston Scientific (BSX) Catches Eye: Stock Jumps 5%
    Zacks

    Boston Scientific (BSX) Catches Eye: Stock Jumps 5%

    Boston Scientific (BSX) saw a big move last session, as its shares jumped 5% on the day, amid huge volumes.

  • Company News For Oct 24, 2019
    Zacks

    Company News For Oct 24, 2019

    Companies In The News Are: ALXN,ANTM,TMO,BSX